Intestinal Research

Original Article

IBD

A nationwide analysis on the influence of obesity in inflammatory bowel disease hospitalizations: Dushyant Singh Dahiya, Asim Kichloo, Farah Wani, Jagmeet Singh, Dhanshree Solanki, Hafeez Shaka; Intest Res 2022;20(3):342-349. Published online May 21, 2021; DOI: https://doi.org/10.5217/ir.2021.00046

Background/Aims
Proinflammatory cytokines released from adipocytes can influence the development, progression, and treatment of inflammatory bowel disease (IBD), and may be associated with worse clinical outcomes.
Methods
For 2016–2018, we analyzed data from the Nationwide Inpatient Sample to identify adult (≥18 years) hospitalizations with a primary discharge diagnosis of IBD. The study sample was divided based on the presence or absence of obesity. The primary outcomes included inpatient mortality, while the secondary outcomes consisted of system-based complications and disease implications on the United States healthcare system.
Results
We identified 282,005 hospitalizations of IBD from 2016 to 2018. Of these hospitalizations, 26,465 (9.4%) had a secondary diagnosis of obesity while 255,540 (90.6%) served as controls. IBD hospitalizations with obesity had a higher mean age (47.9 years vs. 45.2 years, P<0.001), middle age (range, 40–65 years) predominance (37.7% vs. 28.9%, P<0.001), female predominance (64.1% vs. 52.5%, P<0.001) and higher proportion of patients with comorbidities compared to the non-obese cohort. White predominance was observed in both subgroups. No difference in the odds of inpatient mortality was noted between the 2 subgroups; however, IBD hospitalizations with obesity had higher mean total hospital charge ($50,126 vs. $45,001, P<0.001), longer length of stay (5.5 days vs. 4.9 days, P<0.001) and higher proportion of complications compared to the non-obese cohort.
Conclusions
Obese IBD hospitalizations had higher length of stay, total hospital charge, and complications compared to the non-obese cohort.

Citations

Citations to this article as recorded by

Obesity and Chronic Inflammation: Implications for Rheumatoid Arthritis, Spondyloarthritis, and Ulcerative Colitis
Ada Corrado, Ilaria Guadagni, Giovanna Picarelli, Angela Variola
Immunity, Inflammation and Disease.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease: prevalence, risk factors, pathophysiological pathways and clinical consequences
Elena Grueso Navarro, Alfredo J. Lucendo
Expert Review of Clinical Immunology.2025; 21(7): 875. CrossRef
Obesity-Mediated Inflammation and Its Influence on Inflammatory Bowel Disease: Pathophysiology, Clinical Impact, and Therapeutic Implications
Diego Casas-Deza, Santiago García-López, Vanesa Bernal-Monterde, Cristina Polo-Cuadro, Carmen Yagüe-Caballero, José M. Arbones-Mainar
Biomolecules.2025; 15(8): 1185. CrossRef
Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis
Fatemeh Ojaghi Shirmard, Seyed Morteza Pourfaraji, Mahyaar Omouri-Kharashtomi, Arash Amani
BMC Gastroenterology.2025;[Epub] CrossRef
Can GLP-1 agonists be used safely in inflammatory bowel disease? A meta-analysis
Noppachai Siranart, Pannathorn Nakaphan, Patavee Pajareya, Khamik Laohasurayotin
Journal of Crohn's and Colitis.2025;[Epub] CrossRef
Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis
Ahmed B Bayoumy, Lindsay M Clarke, Parakkal Deepak, Aakash Desai, Priya Sehgal, uri Gorelik, Haggai Bar-Yoseph, Marie Villumsen, Chris J J Mulder, Dirk J Stenvers, Maarten E Tushuizen, Nanne K H de Boer
Journal of Crohn's and Colitis.2025;[Epub] CrossRef
Recomendaciones sobre el manejo de la obesidad grave en pacientes con enfermedad inflamatoria intestinal del Grupo Español de Trabajo en Enfermedad Inflamatoria Intestinal (GETECCU), Sociedad Española de Obesidad (SEEDO), Asociación Española de Cirugía (A
Eugeni Domènech, Andreea Ciudin, José María Balibrea, Eduard Espinet-Coll, Fiorella Cañete, Lilliam Flores, Manuel Ferrer-Márquez, Román Turró, Alejandro Hernández-Camba, Yamile Zabana, Ana Gutiérrez, José María Balibrea, Manuel Barreiro-de Acosta, Javier
Gastroenterología y Hepatología.2024; 47(8): 906. CrossRef
The Rising Epidemic of Obesity in Patients with Inflammatory Bowel Disease
Jellyana Peraza, Erin Abbott, Mark Shneyderman, Asher Kornbluth, Maitreyi Raman, Stephanie Gold
Current Treatment Options in Gastroenterology.2024; 22(3): 134. CrossRef
Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish
Eugeni Domènech, Andreea Ciudin, José María Balibrea, Eduard Espinet-Coll, Fiorella Cañete, Lilliam Flores, Manuel Ferrer-Márquez, Román Turró, Alejandro Hernández-Camba, Yamile Zabana, Ana Gutiérrez, José María Balibrea, Manuel Barreiro-de Acosta, Javier
Gastroenterología y Hepatología (English Edition).2024; 47(8): 906. CrossRef
Body Mass Index Profile of Adult Patients with Inflammatory Bowel Disease in a Multicenter Study in Northeastern Brazil
Jones Lima, Carlos Brito, Lívia Celani, Marcelo Vicente Araújo, Maurilio Lucena, Graciana Vasconcelos, Gustavo Lima, Fernando Nóbrega, George Diniz, Norma Lucena-Silva, Regiane Maio, Valéria Martinelli
Clinical and Experimental Gastroenterology.2023; Volume 16: 213. CrossRef
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Ki
Intestinal Research.2022; 20(3): 350. CrossRef

8,321 View
514 Download
10 Web of Science
11 Crossref

First
Prev
Page of 1
Next
Last

Search